NASDAQ:ASND - Ascendis Pharma A/S Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $155.00
  • Forecasted Upside: 40.62 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +5.42 (5.17%)

This chart shows the closing price for ASND by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ascendis Pharma A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASND

Analyst Price Target is $155.00
▲ +40.62% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $155.00, with a high forecast of $180.00 and a low forecast of $117.00. The average price target represents a 40.62% upside from the last price of $110.23.

This chart shows the closing price for ASND for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in Ascendis Pharma A/S. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2022Morgan StanleyLower Price TargetOverweight$152.00 ➝ $148.00Low
8/11/2022OppenheimerLower Price TargetOutperform$154.00 ➝ $144.00Low
8/11/2022SVB LeerinkLower Price TargetOutperform$174.00 ➝ $168.00Low
5/12/2022Cantor FitzgeraldLower Price Target$230.00 ➝ $180.00High
5/12/2022OppenheimerLower Price Target$166.00 ➝ $154.00High
5/12/2022Wells Fargo & CompanyLower Price Target$190.00 ➝ $176.00High
5/12/2022Credit Suisse GroupLower Price Target$194.00 ➝ $123.00High
5/12/2022CitigroupLower Price Target$187.00 ➝ $158.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/28/2022WedbushReiterated RatingOutperformLow
3/15/2022Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $197.00High
3/15/2022SVB LeerinkBoost Price TargetOutperform$190.00 ➝ $193.00High
3/15/2022Bank of AmericaUpgradeNeutral ➝ Buy$148.00 ➝ $161.00High
3/14/2022Wells Fargo & CompanyBoost Price Target$170.00 ➝ $190.00High
3/14/2022Credit Suisse GroupBoost Price TargetOutperform$188.00 ➝ $194.00High
3/7/2022Morgan StanleyLower Price TargetOverweight$197.00 ➝ $180.00Low
3/3/2022WedbushLower Price TargetOutperform$128.00 ➝ $117.00High
3/3/2022Wells Fargo & CompanyLower Price TargetOverweight$176.00 ➝ $170.00High
3/3/2022Credit Suisse GroupLower Price TargetOutperform$196.00 ➝ $188.00High
2/28/2022CitigroupInitiated CoverageBuy$187.00High
2/14/2022OppenheimerUpgradeMarket Perform ➝ Outperform$170.00Medium
1/13/2022WedbushLower Price Target$191.00 ➝ $186.00High
1/6/2022CowenInitiated CoverageMarket PerformMedium
12/16/2021WedbushReiterated RatingOutperform$191.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$176.00Medium
11/18/2021Cantor FitzgeraldReiterated RatingOverweightLow
11/15/2021SVB LeerinkBoost Price TargetOutperform$182.00 ➝ $190.00Medium
11/11/2021Credit Suisse GroupLower Price TargetOutperform$185.00 ➝ $179.00Low
10/20/2021Bank of AmericaDowngradeBuy ➝ Neutral$164.00 ➝ $169.00High
8/26/2021WedbushReiterated RatingBuy$187.00High
8/26/2021Morgan StanleyBoost Price TargetOverweight$197.00 ➝ $204.00High
8/26/2021JPMorgan Chase & Co.Boost Price TargetOverweight$172.00 ➝ $175.00High
8/26/2021Credit Suisse GroupBoost Price TargetOutperform$178.00 ➝ $185.00High
8/26/2021SVB LeerinkBoost Price TargetOutperform$178.00 ➝ $182.00High
7/21/2021SVB LeerinkLower Price TargetOutperform$181.00 ➝ $178.00Low
7/8/2021OppenheimerReiterated RatingHoldMedium
6/14/2021SVB LeerinkLower Price TargetPositive ➝ Outperform$191.00 ➝ $181.00High
6/14/2021WedbushLower Price TargetOutperform$219.00 ➝ $189.00High
6/14/2021Morgan StanleyLower Price TargetOverweight$201.00 ➝ $197.00High
5/28/2021Credit Suisse GroupBoost Price TargetOutperform$176.00 ➝ $178.00High
5/28/2021Morgan StanleyBoost Price TargetOverweight$199.00 ➝ $201.00Medium
3/30/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
3/11/2021Credit Suisse GroupLower Price TargetOutperform$178.00 ➝ $176.00Low
3/11/2021Stifel NicolausInitiated CoverageBuyHigh
12/17/2020Berenberg BankInitiated CoverageBuy$216.00Low
11/13/2020Morgan StanleyBoost Price TargetOverweight$194.00 ➝ $199.00Low
11/12/2020Wells Fargo & CompanyBoost Price TargetOverweight$176.00 ➝ $190.00High
11/12/2020Credit Suisse GroupBoost Price TargetOutperform$158.00 ➝ $178.00High
11/12/2020SVB LeerinkBoost Price TargetOutperform$173.00 ➝ $191.00High
10/13/2020Morgan StanleyBoost Price TargetOverweight$179.00 ➝ $194.00Low
9/30/2020WedbushBoost Price TargetOutperform$187.00 ➝ $206.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightMedium
8/31/2020Morgan StanleyBoost Price TargetOverweight$177.00 ➝ $179.00High
8/28/2020Credit Suisse GroupBoost Price TargetOutperform$154.00 ➝ $158.00Medium
7/15/2020Morgan StanleyLower Price TargetOverweight$181.00 ➝ $177.00Low
6/26/2020WedbushInitiated CoverageBuy$188.00Low
5/21/2020Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $181.00Low
5/20/2020CSFBBoost Price TargetOutperform$149.00 ➝ $154.00Medium
5/20/2020SVB LeerinkBoost Price TargetOutperform$170.00 ➝ $173.00Low
5/20/2020Credit Suisse GroupBoost Price TargetOutperform$149.00 ➝ $154.00High
5/20/2020OppenheimerLower Price TargetOutperform$219.00 ➝ $208.00High
4/20/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$152.00 ➝ $170.00High
4/20/2020JPMorgan Chase & Co.Boost Price TargetOverweight$145.00 ➝ $150.00High
4/20/2020OppenheimerBoost Price TargetOutperform$199.00 ➝ $219.00High
4/20/2020Credit Suisse GroupBoost Price TargetIn-Line ➝ Outperform$139.00 ➝ $149.00High
4/20/2020Cantor FitzgeraldBoost Price TargetOverweight$185.00 ➝ $201.00High
4/20/2020Stifel NicolausBoost Price TargetBuy$146.00 ➝ $171.00High
4/2/2020Morgan StanleyLower Price TargetOverweight$181.00 ➝ $180.00Medium
3/27/2020Bank of AmericaReiterated RatingBuy$145.00Medium
3/19/2020OppenheimerInitiated CoverageOutperform$199.00Low
2/26/2020Morgan StanleyBoost Price TargetOverweight$148.00 ➝ $181.00Low
1/17/2020Morgan StanleyBoost Price TargetOverweight$140.00 ➝ $148.00Medium
12/17/2019Morgan StanleyBoost Price TargetOverweight$134.00 ➝ $140.00High
12/3/2019SVB LeerinkReiterated RatingPositive ➝ Outperform$140.00 ➝ $152.00Medium
11/19/2019WedbushReiterated RatingBuy$186.00High
10/22/2019WedbushLower Price TargetPositive ➝ Outperform$191.00 ➝ $186.00High
10/11/2019Morgan StanleyInitiated CoverageOverweight$128.00High
9/24/2019WedbushSet Price TargetBuy$191.00Low
8/29/2019JPMorgan Chase & Co.Boost Price TargetOverweight$143.00 ➝ $152.00High
6/28/2019WedbushReiterated RatingBuy$223.00Low
6/10/2019WedbushSet Price TargetBuy$223.00Low
6/3/2019WedbushBoost Price TargetOutperform$219.00 ➝ $223.00High
5/20/2019WedbushSet Price TargetBuy$219.00Medium
4/8/2019WedbushReiterated RatingBuy$219.00High
3/29/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$151.00 ➝ $139.00Low
3/26/2019WedbushReiterated RatingBuy$217.00Medium
3/25/2019Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
3/18/2019Cantor FitzgeraldReiterated RatingBuy$185.00Low
3/7/2019WedbushSet Price TargetOutperform$81.00 ➝ $217.00Medium
3/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight$85.00 ➝ $145.00Medium
3/4/2019Cantor FitzgeraldReiterated RatingOverweight$102.00 ➝ $185.00High
1/25/2019WedbushSet Price TargetBuy$81.00High
1/24/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$73.00 ➝ $90.00Low
1/23/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$102.00Low
11/29/2018Credit Suisse GroupBoost Price TargetOutperform$80.00 ➝ $86.00High
11/9/2018Credit Suisse GroupInitiated CoverageOutperform$80.00Low
8/30/2018WedbushSet Price TargetBuy$79.00Low
8/30/2018JPMorgan Chase & Co.Boost Price TargetOverweight$79.00 ➝ $81.00Low
8/30/2018Wells Fargo & CompanyBoost Price TargetOutperform$83.00 ➝ $88.00High
8/30/2018Stifel NicolausLower Price TargetBuy ➝ Buy$85.00 ➝ $81.00High
6/26/2018Stifel NicolausInitiated CoverageBuy$85.00Medium
5/31/2018SVB LeerinkReiterated RatingMarket Perform$64.00 ➝ $70.00Medium
5/15/2018WedbushReiterated RatingOutperform$76.00Low
4/20/2018WedbushReiterated RatingTop Pick$76.00High
4/4/2018WedbushLower Price TargetOutperform$76.00 ➝ $67.00Low
4/2/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$37.00 ➝ $64.00High
3/21/2018JPMorgan Chase & Co.Boost Price TargetOverweight$75.00High
3/20/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $78.00High
2/26/2018WedbushReiterated RatingOutperform$67.00Low
2/25/2018Credit Suisse GroupReiterated RatingBuy$50.00Low
2/6/2018WedbushReiterated RatingOutperform$62.00Low
1/25/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$45.00 ➝ $60.00High
1/19/2018HC WainwrightReiterated RatingBuyMedium
1/17/2018JPMorgan Chase & Co.Reiterated RatingBuy$60.00Medium
1/3/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00Low
12/13/2017HC WainwrightReiterated RatingBuyLow
11/17/2017Bank of AmericaLower Price TargetBuy$46.00 ➝ $43.00N/A
9/28/2017Bank of AmericaBoost Price Target$36.00 ➝ $46.00Low
9/25/2017Bank of AmericaReiterated RatingBuy$34.00 ➝ $36.00High
9/22/2017Wells Fargo & CompanyReiterated RatingBuy$51.00High
9/22/2017Credit Suisse GroupReiterated RatingOutperform$30.00 ➝ $50.00High
9/22/2017WedbushReiterated RatingOutperform$65.00 ➝ $10.71High
9/1/2017SVB LeerinkReiterated RatingHold$28.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Ascendis Pharma A/S logo
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Read More

Today's Range

Now: $110.23
Low: $103.29
High: $110.39

50 Day Range

MA: $89.58
Low: $78.60
High: $110.23

52 Week Range

Now: $110.23
Low: $61.58
High: $178.71


516,110 shs

Average Volume

456,690 shs

Market Capitalization

$6.28 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Ascendis Pharma A/S?

The following Wall Street sell-side analysts have issued stock ratings on Ascendis Pharma A/S in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc.,, SVB Leerink LLC, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ASND.

What is the current price target for Ascendis Pharma A/S?

10 Wall Street analysts have set twelve-month price targets for Ascendis Pharma A/S in the last year. Their average twelve-month price target is $155.00, suggesting a possible upside of 44.5%. Cantor Fitzgerald has the highest price target set, predicting ASND will reach $180.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $117.00 for Ascendis Pharma A/S in the next year.
View the latest price targets for ASND.

What is the current consensus analyst rating for Ascendis Pharma A/S?

Ascendis Pharma A/S currently has 1 hold rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASND will outperform the market and that investors should add to their positions of Ascendis Pharma A/S.
View the latest ratings for ASND.

What other companies compete with Ascendis Pharma A/S?

How do I contact Ascendis Pharma A/S's investor relations team?

Ascendis Pharma A/S's physical mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company's listed phone number is (457) 022-2244 and its investor relations email address is [email protected] The official website for Ascendis Pharma A/S is Learn More about contacing Ascendis Pharma A/S investor relations.